Monte Rosa Therapeutics, Inc. Common Stock vs. Moderna, Inc. Common Stock
GLUE
Monte Rosa Therapeutics, Inc. Common Stock
$12.13 -3.73%
VS MRNAModerna, Inc. Common Stock
$154.04 -2.55%
Monte Rosa Therapeutics, Inc. Common Stock (GLUE) comes out ahead, leading on 3 of 5 compared factors.
Size & Scale
| GLUE | MRNA | |
|---|---|---|
| Market Cap | $1.03 billion | $61.50 billion |
| Revenue (TTM) | — | $2.23 billion |
| Net Income (TTM) | $-161,090,000 | $-3,151,000,000 |
GLUE and MRNA split the size & scale factors evenly.
Valuation
| GLUE | MRNA | |
|---|---|---|
| Price / Book | 2.12 | 9.10 |
| Price / Sales | — | 27.60 |
GLUE leads on 1 of 1 valuation factors.
Profitability
| GLUE | MRNA | |
|---|---|---|
| Net Margin | — | -141.43% |
| Return on Equity | -33.06% | -46.61% |
GLUE leads on 1 of 1 profitability factors.
Risk & Sentiment
| GLUE | MRNA | |
|---|---|---|
| Short Interest | 0.86% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: GLUE overview, GLUE financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.